Inhibrx Biosciences, Inc.
INBX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.18 | -0.10 | 0.72 |
| FCF Yield | -88.37% | -11.05% | -11.74% | -4.89% |
| EV / EBITDA | 0.05 | -8.34 | -7.32 | -21.22 |
| Quality | ||||
| ROIC | -234.02% | -85.73% | -48.36% | -59.05% |
| Gross Margin | -1,042.50% | 33.83% | -4,926.73% | 62.27% |
| Cash Conversion Ratio | -0.12 | 0.81 | 0.79 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | -54.98% | -36.78% | -44.48% | -7.81% |
| Free Cash Flow Growth | 0.45% | -70.62% | -42.86% | -64.57% |
| Safety | ||||
| Net Debt / EBITDA | -0.08 | 0.33 | 0.53 | 0.81 |
| Interest Coverage | -24.57 | -6.89 | -8.02 | -14.68 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -428.74 | -3.06 |
| Cash Conversion Cycle | -710.27 | -2,389.27 | 14.36 | -1,313.32 |